About Brain Vectis
Brain Vectis is a company based in Paris (France) founded in 2015 was acquired by AskBio in April 2020.. Brain Vectis has raised $1.1 million across 1 funding round from investors including AskBio. Brain Vectis offers products and services including AAV Technology Platform, Capsids, Promoters, Pro10™, and neDNA™. Brain Vectis operates in a competitive market with competitors including Biogen, Insitro, BridgeBio, ATAI and Denali Therapeutics, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Askbio Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Brain Vectis
Brain Vectis offers a comprehensive portfolio of products and services, including AAV Technology Platform, Capsids, Promoters, Pro10™, and neDNA™. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides tools for developing AAV-based therapies for genetic diseases.
Viral components used to deliver gene therapies to target cells.
Elements that control gene expression in therapy applications.
Advanced promoter system for improved gene therapy efficacy.
Innovative DNA constructs for gene therapy development.
Processes for scalable production of gene therapy products.
Funding Insights of Brain Vectis
Brain Vectis has successfully raised a total of $1.1M through 1 strategic funding round. The most recent funding activity was a Series A round of $1.1 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $1.1M
-
First Round
First Round
(13 Sep 2016)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2016 | Amount | Series A - Brain Vectis | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Brain Vectis
Brain Vectis has secured backing from 1 investor. Prominent investors backing the company include AskBio. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Gene and protein therapies are developed for treating various diseases.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Brain Vectis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Brain Vectis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Brain Vectis Comparisons
Competitors of Brain Vectis
Brain Vectis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Insitro, BridgeBio, ATAI and Denali Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Brain Vectis
Frequently Asked Questions about Brain Vectis
When was Brain Vectis founded?
Brain Vectis was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is Brain Vectis located?
Brain Vectis is headquartered in Paris, France.
Is Brain Vectis a funded company?
Brain Vectis is a funded company, having raised a total of $1.1M across 1 funding round to date. The company's 1st funding round was a Series A of $1.1M, raised on Sep 13, 2016.
What does Brain Vectis do?
Developer of gene therapies for the treatment of Alzheimers and Huntingtons disease. It is using AAV to deliver CYP46A1, a key enzyme of brain cholesterol metabolism which is impaired in neurodegenerative diseases. CYP46A1 is reduced in the brain of HD and AD patients. Cholesterol accumulates and the cholesterol pathway is slowed down. CYP46A1 turns the excess cholesterol into a derivative able to move freely from the brain to the blood for peripheral elimination.
Who are the top competitors of Brain Vectis?
Brain Vectis's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Brain Vectis offer?
Brain Vectis offers AAV Technology Platform, Capsids, Promoters, Pro10™, and 2 more products and services.
Who are Brain Vectis's investors?
Brain Vectis has 1 investor. Key investors include AskBio.